<DOC>
	<DOCNO>NCT01678443</DOCNO>
	<brief_summary>This phase I trial study side effect best dose monoclonal antibody therapy stem cell transplant treat patient relapsed refractory lymphoid malignancy . Radiolabeled monoclonal antibody , yttrium-90 anti-CD45 monoclonal antibody BC8 , find cancer cell carry cancer-killing substance without harm normal cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Giving radiolabeled monoclonal antibody stem cell transplant may effective treatment relapse refractory lymphoid malignancy .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Before Stem Cell Transplant Treating Patients With Relapsed Refractory Lymphoid Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate maximally tolerate dose ( MTD ) 90Y-BC8-DOTA ( anti-cluster differentiation [ CD ] 45 ) ( yttrium-90 anti-CD45 monoclonal antibody BC8 ) deliver prior autologous stem cell transplantation patient relapsed/refractory B-cell non-Hodgkin lymphoma ( B-NHL ) , T-cell NHL ( T-NHL ) , Hodgkin lymphoma ( HL ) . SECONDARY OBJECTIVES : I . To optimize protein dose ( antibody [ Ab ] ) deliver favorable biodistribution majority patient . II . To describe impact rituximab concentration , B-cell depletion , disease burden CD20 CD45 target . III . To describe response rate remission duration relapse B-NHL , T-NHL , HL follow administration myeloablative dose 90Y-BC8-DOTA prior autologous stem cell transplant ( ASCT ) . IV . To assess correlation lymphoma biomarkers outcomes . OUTLINE : This dose-escalation study yttrium-90 anti-CD45 monoclonal antibody BC8 . Patients receive indium-111 anti-CD45 monoclonal antibody BC8 intravenously ( IV ) day -28 ( necessary ) day -21 evaluate antibody 's biodistribution . Patients receive yttrium-90 anti-CD45 monoclonal antibody BC8 IV day -14 . Patients undergo autologous peripheral blood stem cell transplantation day 0 . After completion study treatment , patient follow 3 , 6 , 12 month annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Leukemia , Large Granular Lymphocytic</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients must histologically confirm diagnosis BNHL , TNHL , HL ; patient classical HL must document histologic demonstration CD45+ cell adjacent Reed Sternberg cell ; patient must receive least one prior standard systemic therapy document recurrent refractory disease ; patient mantle cell lymphoma ( MCL ) , TNHL , highrisk malignancy may enrolled/transplanted complete remission ( CR ) /first partial remission ( PR1 ) Creatinine &lt; 2.0 Bilirubin &lt; 1.5 mg/dL All patient eligible therapeutic study must minimum &gt; = 2 x 10^6 CD34/kg autologous hematopoietic stem cell harvest cryopreserved Patients must expect survival &gt; 60 day must free major infection Patients prefer either tumor mass amenable core needle biopsy dosimetry phase , measurable tumor mass least one site involvement measure 2.5 cm large dimension compute tomography ( CT ) imaging purpose planar and/or singlephoton emission compute tomography ( SPECT ) /CT tumor dosimetry Circulating human antimouse antibody ( HAMA ) , determine infusion Systemic antilymphoma therapy give previous 30 day schedule therapy dose exception rituximab Inability understand give inform consent Lymphoma involve central nervous system Other serious medical condition consider represent contraindication ASCT ( e.g. , abnormally decreased cardiac ejection fraction , diffusion capacity lung carbon monoxide [ DLCO ] &lt; 50 % predict , acquire immune deficiency syndrome [ AIDS ] , etc . ) Known human immunodeficiency virus ( HIV ) seropositivity Pregnancy breast feed Prior allogeneic bone marrow stem cell transplant Prior autologous bone marrow stem cell transplant within 1 year enrollment Prior radiation therapy ( RT ) &gt; 20 Gray ( Gy ) critical organ within 1 year enrollment Southwest Oncology Group ( SWOG ) performance status &gt; = 2.0 Patients relapse diffuse large Bcell lymphoma ( DLBCL ) HL achieve positron emission tomography ( PET ) negative CR follow first salvage chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>